Cargando…

Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy

BACKGROUND-: Data exist that demonstrate isoflavones' potent antiproliferative effects on prostate cancer cells. We evaluated the efficacy of isoflavone in patients with PSA recurrent prostate cancer after prior therapy. We postulated that isoflavone therapy would slow the rate of rise of serum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pendleton, John M, Tan, Winston W, Anai, Satoshi, Chang, Myron, Hou, Wei, Shiverick, Kathleen T, Rosser, Charles J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394534/ https://www.ncbi.nlm.nih.gov/pubmed/18471323 http://dx.doi.org/10.1186/1471-2407-8-132

Ejemplares similares

Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy
por: Gawkowska-Suwinska, Marzena, et al.
Publicado: (2010)

Chemoprevention of Prostate Cancer: Soy Isoflavones and Curcumin
por: Horie, Shigeo
Publicado: (2012)

A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy
por: Kumar, Nagi B., et al.
Publicado: (2020)

The Role of Isoflavones in the Prevention of Breast Cancer and Prostate Cancer
por: Pejčić, Tomislav, et al.
Publicado: (2023)

Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Dundee, Philip, et al.
Publicado: (2022)

Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria
por: Nakamura, Kogenta, et al.
Publicado: (2009)

Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer
por: Kessler, Elizabeth R., et al.
Publicado: (2018)

Isoflavones and Prostate Cancer: A Review of Some Critical Issues
por: Zhang, Hong-Yi, et al.
Publicado: (2016)

Identification and characterization of a major QTL underlying soybean isoflavone malonylglycitin content
por: Watanabe, Satoshi, et al.
Publicado: (2019)

Prostate cancer metastasis and soy isoflavones: a dogfight over a bone
por: Ajdžanovic, Vladimir, et al.
Publicado: (2019)

Interventions on soy isoflavone molecules to improve their therapeutic potential for prostate cancer treatment
por: Ajdžanovic, Vladimir, et al.
Publicado: (2022)

Prostate-Specific Antigen and Prostate-Specific Antigen Velocity as Threshold Indicators in (11)C-Acetate PET/CTAC Scanning for Prostate Cancer Recurrence
por: Dusing, Reginald W., et al.
Publicado: (2014)

The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
por: Mendez, Lucas C., et al.
Publicado: (2023)

Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
por: Tamihardja, Jörg, et al.
Publicado: (2022)

Phase II Trial of Pure Hypofractionated Radiotherapy in the Treatment of Localized Carcinoma of the Prostate
por: Gopaul, Darin, et al.
Publicado: (2018)

The Predictive Role of Prostate-Specific Antigen Changes Following Transurethral Resection of the Prostate for Patients with Localized Prostate Cancer
por: Wu, Chun-Te, et al.
Publicado: (2020)

Short-Term Soy Isoflavone Intervention in Patients with Localized Prostate Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Hamilton-Reeves, Jill M., et al.
Publicado: (2013)

Localization and restaging of carcinoma prostate by (68)Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence
por: Seniaray, Nikhil, et al.
Publicado: (2020)

Timing of supplementation of selenium and isoflavones determines prostate cancer risk factor reduction in rats
por: Tolman, Jessica R, et al.
Publicado: (2008)

AB070. Roles and mechanisms of soybean isoflavones in androgen-independent transformation of prostate cancer
por: Xu, Li, et al.
Publicado: (2017)

Overexpression of claspin promotes docetaxel resistance and is associated with prostate‐specific antigen recurrence in prostate cancer
por: Babasaki, Takashi, et al.
Publicado: (2021)

Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports
por: Xie, Haijie, et al.
Publicado: (2017)

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

Targeting Bone Remodeling by Isoflavone and 3,3′-Diindolylmethane in the Context of Prostate Cancer Bone Metastasis
por: Li, Yiwei, et al.
Publicado: (2012)

Effects of a Soybean Isoflavone Mixture on Carcinogenesis in Prostate and Seminal Vesicles of F344 Rats
por: Onozawa, Mizuki, et al.
Publicado: (1999)

The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer
por: Kase, Adam M., et al.
Publicado: (2022)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
por: Ben Jemaa , Awatef, et al.
Publicado: (2010)

Machine learning methods can more efficiently predict prostate cancer compared with prostate-specific antigen density and prostate-specific antigen velocity
por: Nitta, Satoshi, et al.
Publicado: (2019)

GPX1 Localizes to the Nucleus in Prostate Epithelium and its Levels are not Associated with Prostate Cancer Recurrence
por: Ekoue, Dede N., et al.
Publicado: (2018)

Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer
por: Schmitz, Matthew D, et al.
Publicado: (2010)

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
por: Pinkawa, Michael, et al.
Publicado: (2012)

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy
por: Tomioka, Atsushi, et al.
Publicado: (2015)

Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer
por: Kang, Ho Won, et al.
Publicado: (2016)

The Spontaneous Remission of Recurrent Lymph Node Metastatic Prostate Cancer With Lowering Serum Prostate-Specific Antigen Level
por: Katano, Atsuto, et al.
Publicado: (2022)

A Phase II Trial of a Combination Herbal Supplement for Men with Biochemically Recurrent Prostate Cancer
por: Dorff, Tanya B., et al.
Publicado: (2014)

Diets high in selenium and isoflavones decrease androgen-regulated gene expression in healthy rat dorsolateral prostate
por: Legg, Russell L, et al.
Publicado: (2008)

Prostate specific antigen /
Publicado: (2001)

EMT Markers in Locally-Advanced Prostate Cancer: Predicting Recurrence?
por: Cheaito, Katia A., et al.
Publicado: (2019)

Salvage brachytherapy in combination with interstitial hyperthermia for locally recurrent prostate carcinoma following external beam radiation therapy: a prospective phase II study
por: Kukiełka, Andrzej M., et al.
Publicado: (2015)

A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy
por: Yamada, Yoshiya, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vikcs3fot9a1fttt78fv84co76